What is Nautilus Biotechnology Inc Annual Net Profit?

Nautilus Biotechnology Inc Annual Net Profit fell 11.16% in the last year to $70.78 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Nautilus Biotechnology Inc Price to Earning Ratio?

Nautilus Biotechnology Inc Price to Earning Ratio is -1.39, which is negative.

What is Nautilus Biotechnology Inc Stock Price?

Nautilus Biotechnology Inc Stock Price fell 67.77% and underperformed its sector by 76.92% in the past year.

What is Nautilus Biotechnology Inc Quarterly Net profit?

Nautilus Biotechnology Inc Quarterly Net profit fell 3.35% YoY to $17.59 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

What is Nautilus Biotechnology Inc Debt to Equity Ratio?

Nautilus Biotechnology Inc Debt to Equity Ratio of 0.15 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Nautilus Biotechnology Inc Return on Equity(ROE)?

Nautilus Biotechnology Inc Return on Equity(ROE) for the last financial year was -29.86%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Nautilus Biotechnology Inc Mutual Fund Holding?

Nautilus Biotechnology Inc Mutual Fund Holding decreased by 0.26% in the last quarter to 8.03.

What is Nautilus Biotechnology Inc Institutional Holding?

Nautilus Biotechnology Inc Institutional Holding decreased by 0.03% in the last quarter to 37.69.

How is the Nautilus Biotechnology Inc today?

The Nautilus Biotechnology Inc today is trading in the green, up by 8.33% at 0.78.

How has Nautilus Biotechnology Inc performed historically?

The Nautilus Biotechnology Inc is currently trading up 8.33% on an intraday basis in the past week the index rose 1.30%. The index has been down -61.19% in the past quarter and fell -67.77% in the past year. You can view this in the overview section.

Nautilus Biotechnology Inc XNAS: NAUT

Nautilus Biotechnology Inc Live Share Price Today, Share Analysis and Chart

Name: Nautilus Biotechnology Inc: Is Infosys Ltd. worth buying?
Item: Nautilus Biotechnology Inc
Rating: 0.91608325
Author: Trendlyne DVM scores

Download real time

0.78 0.06 (8.33%)

74.76% Fall from 52W High

134.6K XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Nautilus Biotechnology Inc is on 30 Apr 2025 for the purpose of Nautilus Biotechnology Inc First Quarter Earnings Results for 2025 See details

Nautilus Biotechnology Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	98.4
PE TTM Negative PE TTM Unavailable in chosen country	-1.4
PEG TTM High in industry Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	0.5
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	37.7
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-3.3
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-11.2
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-60.6
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-29.9
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-25.8

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

13.8 / 100

Technically Bearish

22.8 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Nautilus Biotechnology Inc Stock Price Analysis

Day Price Range 8.3% 1 Day return Unavailable in chosen country	0.8 (LTP) 0.70.8 LowHigh
Week Price Range 1.3% 1 Week return Unavailable in chosen country	0.8 (LTP) 0.70.8 LowHigh
Month Price Range -21.2% 1 Month return Unavailable in chosen country	0.8 (LTP) 0.71.1 LowHigh
52 Week Price Range -67.8% 1 Year return Unavailable in chosen country	0.8 (LTP) 0.73.1 LowHigh

View full Share Price History

Nautilus Biotechnology Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Nautilus Biotechnology Inc Stock Analysis

Nautilus Biotechnology Inc stock analysis with key metrics, changes, and trends.

Nautilus Biotechnology Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$70.78 M	11.16%	negative	Annual Net Profit fell 11.16% in the last year to $70.78 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-1.39	-	negative	Price to Earning Ratio is -1.39, which is negative.
Stock Price	$0.78	-67.77%	negative	Stock Price fell 67.77% and underperformed its sector by 76.92% in the past year.
Quarterly Net profit	$17.59 M	3.35%	negative	Quarterly Net profit fell 3.35% YoY to $17.59 M. Its sector's average net profit growth YoY for the quarter was -41.97%.
Debt to Equity Ratio	0.15	-	positive	Debt to Equity Ratio of 0.15 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-29.86 %	-29.86%	negative	Return on Equity(ROE) for the last financial year was -29.86%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	8.03 %	-0.26%	negative	Mutual Fund Holding decreased by 0.26% in the last quarter to 8.03.
Institutional Holding	37.69 %	-0.03%	negative	Institutional Holding decreased by 0.03% in the last quarter to 37.69.

VIEW LESS

Loading data..

Nautilus Biotechnology Inc - Company Profile

What does Nautilus Biotechnology Inc do?

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

Nautilus Biotechnology Inc Management structure

All Gross Remunerations are in USD

Mr. Sujal M. Patel

Chief Executive Officer, President, Secretary and Director

2024

Gross Remuneration

Year

Dr. Parag Mallick, PhD

Chief Scientist and Director

2024

Gross Remuneration

Year

Ms. Anna Mowry

Chief Financial Officer, Principal Accounting Officer and Treasurer

2024

Gross Remuneration

Year

Nautilus Biotechnology Inc Board of directors

All Gross Remunerations are in USD

Mr. Michael Altman, C.F.A.

Independent Director

2025

Gross Remuneration

Year

Dr. Vijay Pande, PhD

Independent Director

2025

Gross Remuneration

Year

Nautilus Biotechnology Inc Live Share Price Today, Share Analysis and Chart

74.76% Fall from 52W High

Nautilus Biotechnology Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Nautilus Biotechnology Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Nautilus Biotechnology Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Nautilus Biotechnology Inc Stock Analysis

Nautilus Biotechnology Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 11.16% in the last year to $70.78 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -1.39, which is negative.

Stock Price fell 67.77% and underperformed its sector by 76.92% in the past year.

Quarterly Net profit fell 3.35% YoY to $17.59 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio of 0.15 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -29.86%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.26% in the last quarter to 8.03.

Institutional Holding decreased by 0.03% in the last quarter to 37.69.

Nautilus Biotechnology Inc - Company Profile

What does Nautilus Biotechnology Inc do?

Nautilus Biotechnology Inc Management structure

Mr. Sujal M. Patel

Chief Executive Officer, President, Secretary and Director

Dr. Parag Mallick, PhD

Chief Scientist and Director

Ms. Anna Mowry

Chief Financial Officer, Principal Accounting Officer and Treasurer

Nautilus Biotechnology Inc Board of directors

Mr. Michael Altman, C.F.A.

Independent Director

Dr. Vijay Pande, PhD

Independent Director

Nautilus Biotechnology Inc FAQ

How is Nautilus Biotechnology Inc today?

Nautilus Biotechnology Inc today is trading in the green, and is up by 8.33% at 0.78.

How has Nautilus Biotechnology Inc performed historically?

Nautilus Biotechnology Inc is currently trading up 8.33% on an intraday basis. In the past week the stock rose 1.30%. stock has been down -61.19% in the past quarter and fell -67.77% in the past year. You can view this in the overview section.